Yu-Waye Chu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Yu-Waye Chu

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

The Lancet. Haematology|April 3, 2019

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.

Science Translational Medicine|May 15, 2015

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.

Molecular Cancer Therapeutics|April 20, 2013

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

The Lancet. Haematology|April 3, 2019

Science Translational Medicine|May 15, 2015

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.

Molecular Cancer Therapeutics|April 20, 2013

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.

Pageof 3